Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.50 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 7/20 | 0.49 |
| ▸ | DRD3 | P35462 | 7/20 | 0.49 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | CCR3 | P51677 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437957 | 0.97 | SLC5A7 (0.51) | SLC5A7CCR2DRD2DRD3DRD4 | |
| SCHEMBL12437948 | 0.94 | SLC5A7 (0.56) | SLC5A7MEN1KMT2AALDH1A1CCR3 | |
| SCHEMBL12437947 | 0.93 | SLC5A7 (0.56) | SLC5A7MEN1KMT2AALDH1A1CCR3 | |
| SCHEMBL12437349 | 0.91 | SLC5A7 (0.53) | SLC5A7DRD2DRD3DRD4SMYD2 | |
| SCHEMBL14435668 | 0.90 | SLC5A7 (0.50) | SLC5A7DRD2DRD3MEN1KMT2A | |
| SCHEMBL12437352 | 0.89 | SLC5A7 (0.49) | SLC5A7DRD2DRD3DRD4SMYD2 | |
| SCHEMBL12437963 | 0.87 | CACNA1G (0.52) | ALDH1A1 | |
| SCHEMBL12437354 | 0.87 | DRD2 (0.56) | SLC5A7CCR2DRD2DRD3SMYD2 | |
| SCHEMBL12437952 | 0.86 | MEN1 (0.46) | MEN1KMT2AALDH1A1OPRM1OPRD1 | |
| SCHEMBL12437332 | 0.86 | UTS2R (0.55) | SLC5A7SMYD2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| WO-2007098086-A2 | HYDROXYPIPERIDINE DERIVATIVES AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | SLC5A7 4329/4885CCR2 3522/4885DRD2 1842/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | SLC5A7 4329/4885CCR2 3522/4885DRD2 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.